Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection  Elisabetta Degasperi, Roberta D’Ambrosio, Massimo Iavarone, Angelo Sangiovanni, Alessio Aghemo, Roberta Soffredini, Marta Borghi, Giovanna Lunghi, Massimo Colombo, Pietro Lampertico  Clinical Gastroenterology and Hepatology  Volume 17, Issue 6, Pages 1183-1191.e7 (May 2019) DOI: 10.1016/j.cgh.2018.10.038 Copyright © 2019 AGA Institute Terms and Conditions

Figure 1 Patient disposition. Clinical Gastroenterology and Hepatology 2019 17, 1183-1191.e7DOI: (10.1016/j.cgh.2018.10.038) Copyright © 2019 AGA Institute Terms and Conditions

Figure 2 Cumulative probability of de novo and recurrent HCC among the 505 patients without HCC history and 60 patients with previous HCC history, respectively. Clinical Gastroenterology and Hepatology 2019 17, 1183-1191.e7DOI: (10.1016/j.cgh.2018.10.038) Copyright © 2019 AGA Institute Terms and Conditions

Figure 3 Cumulative probability of de novo HCC according to gender (A), diabetes (B), LSM (C), and FIB-4 (D). Clinical Gastroenterology and Hepatology 2019 17, 1183-1191.e7DOI: (10.1016/j.cgh.2018.10.038) Copyright © 2019 AGA Institute Terms and Conditions

Figure 4 Proportion of patients with de novo HCC according to combination of independent risk factors (male gender, diabetes, LSM >30 kPa, and FIB-4 >9). DM, diabetes mellitus. Clinical Gastroenterology and Hepatology 2019 17, 1183-1191.e7DOI: (10.1016/j.cgh.2018.10.038) Copyright © 2019 AGA Institute Terms and Conditions

Supplementary Figure 1 De novo and recurrent HCC distribution during study period according to time intervals from baseline (3–6, 6–12, or 12–24 months). Clinical Gastroenterology and Hepatology 2019 17, 1183-1191.e7DOI: (10.1016/j.cgh.2018.10.038) Copyright © 2019 AGA Institute Terms and Conditions